Trastuzumab is a therapeutic monoclonal antibody specific for the human epidermal growth factor receptor type 2 (HER2), a cell-surface tyrosine kinase receptor overexpressed in approximately 30% of breast cancers. Here, ERBB2 is linked to breast carcinoma.